Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Dec, 2016 | Pages:
1656 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Melanoma - Pipeline Review, H2 2016 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Melanoma - Pipeline Review, H2 2016, provides an overview of the Melanoma (Oncology) pipeline landscape. Melanoma is a tumor that develops as a result of the malignant transformation of melanocytes. These cells are derived from the neural crest. Melanomas usually occur on the skin but can arise in other locations where neural crest cells migrate, such as in the gastrointestinal tract or brain. It is more common in women than in men. In women, the most common site is the legs and melanomas in men are most common on the back. Unusual moles, sores, lumps, blemishes, markings, or changes in the way an area of the skin looks or feels are sign of melanoma. Treatment includes surgery, radiation and proton therapy. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Melanoma - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Melanoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Melanoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Melanoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 17, 92, 111, 3, 208, 24 and 2 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, Preclinical and Discovery stages comprises 2, 14, 10, 62 and 12 molecules, respectively. Melanoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Melanoma (Oncology). - The pipeline guide reviews pipeline therapeutics for Melanoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Melanoma (Oncology) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Melanoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Melanoma (Oncology) Reasons To Buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Melanoma (Oncology). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Melanoma (Oncology) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2 Introduction 13 Melanoma Overview 14 Therapeutics Development 15 Melanoma - Therapeutics under Development by Companies 17 Melanoma - Therapeutics under Investigation by Universities/Institutes 38 Melanoma - Pipeline Products Glance 43 Melanoma - Products under Development by Companies 47 Melanoma - Products under Investigation by Universities/Institutes 76 Melanoma - Companies Involved in Therapeutics Development 82 Melanoma - Therapeutics Assessment 338 Drug Profiles 391 Melanoma - Dormant Projects 1537 Melanoma - Discontinued Products 1580 Melanoma - Product Development Milestones 1585 Appendix 1598
List of Tables
Number of Products under Development for Melanoma, H2 2016 72 Number of Products under Development for Melanoma - Comparative Analysis, H2 2016 73 Number of Products under Development by Companies, H2 2016 74 Number of Products under Development by Companies, H2 2016 (Contd..1) 75 Number of Products under Development by Companies, H2 2016 (Contd..2) 76 Number of Products under Development by Companies, H2 2016 (Contd..3) 77 Number of Products under Development by Companies, H2 2016 (Contd..4) 78 Number of Products under Development by Companies, H2 2016 (Contd..5) 79 Number of Products under Development by Companies, H2 2016 (Contd..6) 80 Number of Products under Development by Companies, H2 2016 (Contd..7) 81 Number of Products under Development by Companies, H2 2016 (Contd..8) 82 Number of Products under Development by Companies, H2 2016 (Contd..9) 83 Number of Products under Development by Companies, H2 2016 (Contd..10) 84 Number of Products under Development by Companies, H2 2016 (Contd..11) 85 Number of Products under Development by Companies, H2 2016 (Contd..12) 86 Number of Products under Development by Companies, H2 2016 (Contd..13) 87 Number of Products under Development by Companies, H2 2016 (Contd..14) 88 Number of Products under Development by Companies, H2 2016 (Contd..15) 89 Number of Products under Development by Companies, H2 2016 (Contd..16) 90 Number of Products under Development by Companies, H2 2016 (Contd..17) 91 Number of Products under Development by Companies, H2 2016 (Contd..18) 92 Number of Products under Development by Companies, H2 2016 (Contd..19) 93 Number of Products under Development by Companies, H2 2016 (Contd..20) 94 Number of Products under Investigation by Universities/Institutes, H2 2016 95 Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..1) 96 Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..2) 97 Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..3) 98 Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..4) 99 Comparative Analysis by Late Stage Development, H2 2016 100 Comparative Analysis by Clinical Stage Development, H2 2016 101 Comparative Analysis by Early Stage Development, H2 2016 102 Comparative Analysis by Unknown Stage Development, H2 2016 103 Products under Development by Companies, H2 2016 104 Products under Development by Companies, H2 2016 (Contd..1) 105 Products under Development by Companies, H2 2016 (Contd..2) 106 Products under Development by Companies, H2 2016 (Contd..3) 107 Products under Development by Companies, H2 2016 (Contd..4) 108 Products under Development by Companies, H2 2016 (Contd..5) 109 Products under Development by Companies, H2 2016 (Contd..6) 110 Products under Development by Companies, H2 2016 (Contd..7) 111 Products under Development by Companies, H2 2016 (Contd..8) 112 Products under Development by Companies, H2 2016 (Contd..9) 113 Products under Development by Companies, H2 2016 (Contd..10) 114 Products under Development by Companies, H2 2016 (Contd..11) 115 Products under Development by Companies, H2 2016 (Contd..12) 116 Products under Development by Companies, H2 2016 (Contd..13) 117 Products under Development by Companies, H2 2016 (Contd..14) 118 Products under Development by Companies, H2 2016 (Contd..15) 119 Products under Development by Companies, H2 2016 (Contd..16) 120 Products under Development by Companies, H2 2016 (Contd..17) 121 Products under Development by Companies, H2 2016 (Contd..18) 122 Products under Development by Companies, H2 2016 (Contd..19) 123 Products under Development by Companies, H2 2016 (Contd..20) 124 Products under Development by Companies, H2 2016 (Contd..21) 125 Products under Development by Companies, H2 2016 (Contd..22) 126 Products under Development by Companies, H2 2016 (Contd..23) 127 Products under Development by Companies, H2 2016 (Contd..24) 128 Products under Development by Companies, H2 2016 (Contd..25) 129 Products under Development by Companies, H2 2016 (Contd..26) 130 Products under Development by Companies, H2 2016 (Contd..27) 131 Products under Development by Companies, H2 2016 (Contd..28) 132 Products under Investigation by Universities/Institutes, H2 2016 133 Products under Investigation by Universities/Institutes, H2 2016 (Contd..1) 134 Products under Investigation by Universities/Institutes, H2 2016 (Contd..2) 135 Products under Investigation by Universities/Institutes, H2 2016 (Contd..3) 136 Products under Investigation by Universities/Institutes, H2 2016 (Contd..4) 137 Products under Investigation by Universities/Institutes, H2 2016 (Contd..5) 138 Melanoma - Pipeline by 4SC AG, H2 2016 139 Melanoma - Pipeline by AB Science SA, H2 2016 140 Melanoma - Pipeline by AbbVie Inc, H2 2016 141 Melanoma - Pipeline by Abivax SA, H2 2016 142 Melanoma - Pipeline by Acetylon Pharmaceuticals Inc, H2 2016 143 Melanoma - Pipeline by Adamis Pharmaceuticals Corp, H2 2016 144 Melanoma - Pipeline by Adaptimmune Therapeutics Plc, H2 2016 145 Melanoma - Pipeline by Adicet Bio Inc, H2 2016 146 Melanoma - Pipeline by Aduro BioTech Inc, H2 2016 147 Melanoma - Pipeline by Advanced Cancer Therapeutics, H2 2016 148 Melanoma - Pipeline by Advaxis Inc, H2 2016 149 Melanoma - Pipeline by Aeterna Zentaris Inc, H2 2016 150 Melanoma - Pipeline by Affichem SA, H2 2016 151 Melanoma - Pipeline by Agalimmune Ltd, H2 2016 152 Melanoma - Pipeline by Agenus Inc, H2 2016 153 Melanoma - Pipeline by Agilvax Inc, H2 2016 154 Melanoma - Pipeline by AGV Discovery SAS, H2 2016 155 Melanoma - Pipeline by AIMM Therapeutics BV, H2 2016 156 Melanoma - Pipeline by Alethia Biotherapeutics Inc, H2 2016 157 Melanoma - Pipeline by Altor BioScience Corp, H2 2016 158 Melanoma - Pipeline by Amgen Inc, H2 2016 159 Melanoma - Pipeline by Anavex Life Sciences Corp, H2 2016 160 Melanoma - Pipeline by Angimmune LLC, H2 2016 161 Melanoma - Pipeline by Antibe Therapeutics Inc, H2 2016 162 Melanoma - Pipeline by Antigen Express Inc, H2 2016 163 Melanoma - Pipeline by APEIRON Biologics AG, H2 2016 164 Melanoma - Pipeline by Apexigen Inc, H2 2016 165 Melanoma - Pipeline by Aphios Corp, H2 2016 166 Melanoma - Pipeline by APO-T BV, H2 2016 167 Melanoma - Pipeline by Apogenix GmbH, H2 2016 168 Melanoma - Pipeline by Aposense Ltd, H2 2016 169 Melanoma - Pipeline by Aptose Biosciences Inc, H2 2016 170 Melanoma - Pipeline by Arisaph Pharmaceuticals Inc, H2 2016 171 Melanoma - Pipeline by ARMO Biosciences Inc, H2 2016 172 Melanoma - Pipeline by Array BioPharma Inc, H2 2016 173 Melanoma - Pipeline by Asana BioSciences LLC, H2 2016 174 Melanoma - Pipeline by Astellas Pharma Inc, H2 2016 175 Melanoma - Pipeline by Astex Pharmaceuticals Inc, H2 2016 176 Melanoma - Pipeline by AstraZeneca Plc, H2 2016 177 Melanoma - Pipeline by Aurigene Discovery Technologies Ltd, H2 2016 178 Melanoma - Pipeline by Azaya Therapeutics Inc, H2 2016 179 Melanoma - Pipeline by Basilea Pharmaceutica Ltd, H2 2016 180 Melanoma - Pipeline by Batu Biologics Inc, H2 2016 181 Melanoma - Pipeline by Bayer AG, H2 2016 182 Melanoma - Pipeline by BeiGene Ltd, H2 2016 183 Melanoma - Pipeline by Beijing Kawin Technology Share-Holding Co Ltd, H2 2016 184 Melanoma - Pipeline by Bellicum Pharmaceuticals Inc, H2 2016 185 Melanoma - Pipeline by BerGenBio AS, H2 2016 186 Melanoma - Pipeline by Bio-Cancer Treatment International Ltd, H2 2016 187 Melanoma - Pipeline by Biocad, H2 2016 188 Melanoma - Pipeline by Biogazelle NV, H2 2016 189 Melanoma - Pipeline by Biogenomics Ltd, H2 2016 190 Melanoma - Pipeline by BioLineRx Ltd, H2 2016 191 Melanoma - Pipeline by Bioncotech Therapeutics SL, H2 2016 192 Melanoma - Pipeline by Bionomics Ltd, H2 2016 193 Melanoma - Pipeline by BioNTech AG, H2 2016 194 Melanoma - Pipeline by Biothera Pharmaceutical Inc, H2 2016 195 Melanoma - Pipeline by Biovista Inc, H2 2016 196 Melanoma - Pipeline by Boehringer Ingelheim GmbH, H2 2016 197 Melanoma - Pipeline by Boston Biomedical Inc, H2 2016 198 Melanoma - Pipeline by Bristol-Myers Squibb Company, H2 2016 199 Melanoma - Pipeline by Calithera Biosciences Inc, H2 2016 200 Melanoma - Pipeline by Can-Fite BioPharma Ltd, H2 2016 201 Melanoma - Pipeline by CCRP Therapeutics GmbH, H2 2016 202 Melanoma - Pipeline by Cellceutix Corp, H2 2016 203 Melanoma - Pipeline by Celldex Therapeutics Inc, H2 2016 204 Melanoma - Pipeline by Celprogen Inc, H2 2016 205 Melanoma - Pipeline by Celyad SA, H2 2016 206 Melanoma - Pipeline by Checkmate Pharmaceuticals Inc, H2 2016 207 Melanoma - Pipeline by Chipscreen Biosciences Ltd, H2 2016 208 Melanoma - Pipeline by Chugai Pharmaceutical Co Ltd, H2 2016 209 Melanoma - Pipeline by Cipher Pharmaceuticals Inc, H2 2016 210 Melanoma - Pipeline by Cornerstone Pharmaceuticals Inc, H2 2016 211 Melanoma - Pipeline by Cortice Biosciences Inc, H2 2016 212 Melanoma - Pipeline by Corvus Pharmaceuticals Inc, H2 2016 213 Melanoma - Pipeline by CytomX Therapeutics Inc, H2 2016 214 Melanoma - Pipeline by Cytune Pharma SAS, H2 2016 215 Melanoma - Pipeline by CyTuVax BV, H2 2016 216 Melanoma - Pipeline by CZ BioMed Corp, H2 2016 217 Melanoma - Pipeline by Daiichi Sankyo Company Ltd, H2 2016 218 Melanoma - Pipeline by Deciphera Pharmaceuticals LLC, H2 2016 219 Melanoma - Pipeline by DEKK-TEC Inc, H2 2016 220 Melanoma - Pipeline by Dicerna Pharmaceuticals Inc, H2 2016 221 Melanoma - Pipeline by DormaTarg Inc, H2 2016 222 Melanoma - Pipeline by Dynavax Technologies Corp, H2 2016 223 Melanoma - Pipeline by Eisai Co Ltd, H2 2016 224 Melanoma - Pipeline by Eli Lilly and Company, H2 2016 225 Melanoma - Pipeline by Elsalys Biotech SAS, H2 2016 226 Melanoma - Pipeline by Ensol Biosciences Inc, H2 2016 227 Melanoma - Pipeline by EntreChem SL, H2 2016 228 Melanoma - Pipeline by eTheRNA Immunotherapies NV, H2 2016 229 Melanoma - Pipeline by Evelo Therapeutics Inc, H2 2016 230 Melanoma - Pipeline by Exelixis Inc, H2 2016 231 Melanoma - Pipeline by F. Hoffmann-La Roche Ltd, H2 2016 232 Melanoma - Pipeline by Faes Farma SA, H2 2016 233 Melanoma - Pipeline by Five Prime Therapeutics Inc, H2 2016 234 Melanoma - Pipeline by Formune SL, H2 2016 235 Melanoma - Pipeline by Galapagos NV, H2 2016 236 Melanoma - Pipeline by Galectin Therapeutics Inc, H2 2016 237 Melanoma - Pipeline by Genelux Corp, H2 2016 238 Melanoma - Pipeline by Genocea Biosciences Inc, H2 2016 239 Melanoma - Pipeline by Genzyme Corp, H2 2016 240 Melanoma - Pipeline by GlaxoSmithKline Plc, H2 2016 241
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
